TARP as antigen in cancer immunotherapy Jolien VanhoorenCharlotte DerpoorterTim Lammens Review 29 May 2021 Pages: 3061 - 3068
Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis E. Suazo-ZepedaM. BokernG. Sidorenkov Review Open access 30 June 2021 Pages: 3069 - 3080
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients Takeshi IshikawaShinichi KageyamaHiroshi Shiku Original Article 22 March 2021 Pages: 3081 - 3091
Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine Kyp L. OxleyBrett M. HansonGail A. Bishop Original Article 25 March 2021 Pages: 3093 - 3103
Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area Gregory R. StrohTobias PeikertPatricio Escalante Original Article 26 March 2021 Pages: 3105 - 3111
Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer Won Ik SeoChan Ho LeeInhak Choi Original Article 26 March 2021 Pages: 3113 - 3122
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy Danielle VerverDirk J. GrünhagenAstrid A. M. van der Veldt Original Article Open access 27 March 2021 Pages: 3123 - 3135
Distinct genomic features across cytolytic subgroups in skin melanoma Constantinos RoufasIlias Georgakopoulos-SoaresApostolos Zaravinos Original Article Open access 29 March 2021 Pages: 3137 - 3154
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer Kristina WittSusan Evans-AxelssonRebecka Hellsten Original Article Open access 31 March 2021 Pages: 3155 - 3166
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses Jesper van Eck van der SluijsDiede van EnsWillemijn Hobo Original Article Open access 01 April 2021 Pages: 3167 - 3181
Cancer therapy in mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen Marco StringhiniIlaria SpadaforaDario Neri Original Article Open access 01 April 2021 Pages: 3183 - 3197
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab Wei-Xiang QiYi XiangJiayi Chen Original Article 01 April 2021 Pages: 3199 - 3206
Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis Min-Ke HeChuan PengMing Shi Original Article 03 April 2021 Pages: 3207 - 3216
Enhancement of innate and adaptive anti-tumor immunity by serum obtained from vascular photodynamic therapy-cured BALB/c mouse Ying ZhangYing-Kit CheungWing-Ping Fong Original Article 05 April 2021 Pages: 3217 - 3233
CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer Xuehui WuXiaoliang LanLi Liang Original Article Open access 05 April 2021 Pages: 3235 - 3248
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used Vanessa S. FearCatherine A. ForbesBruce W. S. Robinson Original Article Open access 09 April 2021 Pages: 3249 - 3258
Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used Vanessa S. FearCatherine A. ForbesBruce W. S. Robinson Correction Open access 05 June 2021 Pages: 3259 - 3259
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation Pingfeng ChenYoujun DuanShimin Liu Original Article 10 April 2021 Pages: 3261 - 3275
Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program Javier Arranz-NicolásMiguel Martin-SalgadoIsabel Merida Original Article 10 April 2021 Pages: 3277 - 3289
Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens Junxia GaoXianlin YuanLiangping Li Original Article 14 April 2021 Pages: 3291 - 3302
Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations Ondrej UherVeronika CaisovaJan Zenka Original Article 15 April 2021 Pages: 3303 - 3312
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study H. M. StegeM. HaistC. Loquai Original Article Open access 18 April 2021 Pages: 3313 - 3322
Identification of mouse helper epitopes for WT1-specific CD4+ T cells Hiroko NakajimaJun NakataHaruo Sugiyama Original Article 16 July 2021 Pages: 3323 - 3335
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186 Cameron J. HertingMatthew R. FarrenGregory B. Lesinski Clinical Trial Report 23 June 2021 Pages: 3337 - 3348
Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma Beatrice DozinGrazia CarbottiMarina Fabbi Research Report 18 May 2021 Pages: 3349 - 3355
Immune checkpoint inhibitors-induced nephropathy: a French national survey Alexandre O. GérardMarine Andreanithe French Network of Pharmacovigilance Centers Research Report 21 June 2021 Pages: 3357 - 3364
Correction to: Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer Łukasz ZadkaMariusz ChabowskiPiotr Dzięgiel Correction Open access 13 September 2021 Pages: 3365 - 3365
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells J. M. R. Van der MeerR. J. A. MaasH. Dolstra Correction Open access 15 September 2021 Pages: 3367 - 3367